Potassium-competitive acid blockers: Clinical pearls and practical insights.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 42225381.
- Also identified by DOI 10.3949/ccjm.93a.25070.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Potassium-competitive acid blockers (P-CABs) are a new class of acid-suppressing drugs; to date, only one of them (vonoprazan) has been approved for use in the United States. The authors of this article review how P-CABs (and vonoprazan in particular) differ from proton pump inhibitors (PPIs), evidence supporting their effectiveness, indications for vonoprazan, and ongoing and future studies.
Medical subject headings
- Pyrroles
- Proton Pump Inhibitors
- Sulfonamides
- Gastroesophageal Reflux